Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Controlled-release doxazosin in the treatment of benign prostatic hyperplasia

Prostate Cancer and Prostatic Diseases volume 8, pages 375–380 (2005)Cite this article

Abstract

Purpose:

To evaluate the effectiveness and safety of controlled-release doxazosin for benign prostatic hyperplasia (BPH).

Scope:

In this open-label, noncontrolled, observational surveillance study, 3684 men with BPH received 4–8 mg of controlled-release doxazosin gastrointestinal therapeutic system (GITS) for 6 months; 3283 (89.1%) patients completed the trial. Changes in urinary symptoms and quality of life were assessed using the International Prostate Symptom Score (IPSS). Blood pressure and adverse events were assessed.

Conclusion:

After 6 months’ treatment with doxazosin GITS resulted in significant improvements in IPSS. BP was reduced only in hypertensive patients. Doxazosin, GITS was well tolerated.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Chicharro-Molero JA et al. Prevalence of benign prostatic hyperplasia in Spanish men 40 y old or older. J Urol 1998; 159: 878–882.

    Article  CAS  Google Scholar 

  2. Tsukamoto T et al. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J Urol 1995; 154 (Part 1): 391–395.

    Article  CAS  Google Scholar 

  3. Sagnier P et al. Results of an epidemiological survey using a modified American Urological Association symptom index for benign prostatic hyperplasia in France. J Urol 1994; 151: 1266–1270.

    Article  CAS  Google Scholar 

  4. Berry SJ, Coffey DS, Walsh PC, Ewing LL . The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474–479.

    Article  CAS  Google Scholar 

  5. Caine M, Perlberg S, Meretyk S . A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 1978; 50: 551–554.

    Article  CAS  Google Scholar 

  6. Shapiro A, Mazouz B, Caine M . The alpha-adrenergic blocking effect of prazosin on the human prostate. Urol Res 1981; 9: 17–20.

    Article  CAS  Google Scholar 

  7. Boyle P, Napalkov P . Epidemiology of benign prostatic hyperplasia: current perspectives. Eur Urol 1996; 29 (suppl 1): 7–11.

    Article  Google Scholar 

  8. Grimm RJ et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA 1996; 275: 1549–1556.

    Article  CAS  Google Scholar 

  9. Pool J . Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension. Am J Cardiol 1987; 59: 46G–50G.

    Article  CAS  Google Scholar 

  10. Ishimitsu T et al. Long-term effects of doxazosin, an alpha 1-blocker, on serum lipids in hypertensive patients. Hypertens Res 1996; 19: 43–49.

    Article  CAS  Google Scholar 

  11. Chung M et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 1999; 48: 678–687.

    Article  CAS  Google Scholar 

  12. Roehrborn CG, Kirby R, Prajsner A, Anderson M . A double-blind, placebo-controlled study evaluating the onset of action of doxazosin GITS for the treatment of patients with BPH (Abst 921). J Urol 2004; 171 (suppl): 244.

    Article  Google Scholar 

  13. Kirby RS et al. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. Bri J Urol Int 2001; 87: 192–200.

    Article  CAS  Google Scholar 

  14. Hernandez C et al. Hiperplasia benigna prostatica e hipertension arterial. Eficacia del tratamiento con alfabloqueantes. Urol Integr Invest 1998; 3: 69–73.

    Google Scholar 

  15. Kirby RS . Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology 1995; 46: 182–186.

    Article  CAS  Google Scholar 

  16. Black HR . Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension. J Cardiovasc Pharmacol 2003; 41: 866–869.

    Article  CAS  Google Scholar 

  17. Black HR, Sollins JS, Garofalo JL . The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study. Am J Hypertens 2000; 13 (Part 1): 468–474.

    Article  CAS  Google Scholar 

  18. Langdon CG, Packard RS . Doxazosin in hypertension: results of a general practice study in 4809 patients. Br J Clin Pract 1994; 48: 293–298.

    PubMed  CAS  Google Scholar 

  19. Pool JL . Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient. Br J Clin Pract Suppl 1994; 74: 8–12.

    PubMed  CAS  Google Scholar 

  20. Carruthers G et al. Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. Am J Cardiol 1993; 71: 575–581.

    Article  CAS  Google Scholar 

  21. Langdon C . Doxazosin: a study in a cohort of patients with hypertension in general practice - an interim report. Am Heart J 1991; 121: 268–273.

    Article  CAS  Google Scholar 

  22. McConnell JD et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387–2398.

    Article  CAS  Google Scholar 

  23. Kirby RS, Quinn S, Mallen S, Jensen D . Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis. Int J Clin Pract 2004; 58: 6–10.

    Article  CAS  Google Scholar 

  24. De Reijke TM, Klarskov P . Comparative efficacy and tolerability of two a1-Adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms due to benign prostatic enlargement. Bri J Urol Int 2004; 93: 757–762.

    Article  CAS  Google Scholar 

  25. Kirby RS, O’Leary M P, Carson C . Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. Bri J Urol Int 2005; 95: 103–109.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The study was funded by a grant from Pfizer Inc.

Author information

Authors and Affiliations

  1. Hospital General Universitario Gregorio Marañón, Madrid, Spain

    C Hernandez, R Duran, J Jara, I Castaño & M Moralejo

Authors
  1. C Hernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Duran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Jara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I Castaño
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Moralejo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Hernandez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hernandez, C., Duran, R., Jara, J. et al. Controlled-release doxazosin in the treatment of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 8, 375–380 (2005). https://doi.org/10.1038/sj.pcan.4500820

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500820

Keywords

This article is cited by

Search

Advanced search

Quick links